AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02794129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Study NCT04207177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500 mg Tab
Description: Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
Study NCT04207177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
Study NCT03282669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine administered in the operating room.
Study NCT00010257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
Study NCT00010257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
Study NCT02627079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily SMS text messaging
Study NCT03894995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Installation of ventilation
Description: The intervention is installation of a ventilating structure, in this case a window in the house roof.
Study NCT01549145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimbus Multifunctional Stimulator
Description: A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
Study NCT01491022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampyra first, then Placebo
Description: 10 mg po bid for 4 weeks followed by placebo 4 weeks.
Study NCT01491022 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo first, then Ampyra
Description: placebo
Study NCT02425137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1/Gemcitabine
Description: Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
Study NCT00313729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Chemotherapy
Study NCT03790410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex pulmonary rehabilitation
Description: Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
Study NCT03790410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The training program contains strengthening exercises on the diaphragm muscle.
Study NCT01179607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M0002
Study NCT01179607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03320707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
Study NCT03320707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
Study NCT03320707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
Study NCT00843141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive computerized training
Description: cognitive computerized training utilizing executive attention tasks
Study NCT00843141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: simple cognitive computerized training
Description: simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
Study NCT01071174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
Study NCT01071174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Ring containing no drug substance
Study NCT03622762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Capsules of green tea extract, 400 mg twice a day, fasting
Study NCT03622762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 400 mg twice daily fasting
Study NCT03795480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOOD
Description: MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
Study NCT02510937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Study NCT03569501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: 500 mg DHA tablets
Study NCT03569501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 500 mg DHA tablets
Study NCT03569501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oat grains
Description: 90 mg oat, containing 4.05 mg β-glucan
Study NCT03569501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat grains
Description: 90 mg oat, containing 4.05 mg β-glucan
Study NCT01126099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: 4 mg capsules twice daily for 12 weeks
Study NCT01126099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily for 12 weeks
Study NCT02453464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevacizumab
Description: escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
Study NCT02453464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT02453464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
Study NCT02453464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT04531124 — intervention group
Intervention type: OTHER
Intervention: integrated management
Description: establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
Study NCT00729521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: facilitative system
Description: The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
Study NCT00729521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program
Description: a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;
Study NCT03221114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychological Intervention
Description: Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
Study NCT01116336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
Study NCT01116336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Polyphenon E
Description: Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
Study NCT03695146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced breathing
Description: Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
Study NCT03695146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active relaxation
Description: Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
Study NCT02626416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenZOC (mobile application)
Description: The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
Study NCT02850094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Bonuses
Description: Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
Study NCT00712452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biology and ultrasonography after chemotherapy
Description: Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Study NCT01423825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sub C gp140 Vaccine
Description: 100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
Study NCT01423825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1 Adjuvant
Description: MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
Study NCT01423825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
Study NCT03814564 — intervention group
Intervention type: DEVICE
Intervention: NIRS monitoring
Description: Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
Study NCT01190891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Physical Therapy
Description: Same as arm description
Study NCT01190891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Study NCT00044291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atamestane
Study NCT00044291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Study NCT00044291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Study NCT00044291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase inhibition
Study NCT03282669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous hydromorphone
Description: Intravenous hydromorphone administered via IV in the post operative area.
Study NCT01255631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF Device
Description: The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks.
Study NCT01255631 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF Device
Description: Inactive PEMF device, delivers no PMF
Study NCT02768532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed.
Study NCT00633646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diets contained different levels of protein
Description: diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
Study NCT00964275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic procedure
Description: Standard diagnostic procedures followed
Study NCT00964275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: PET with flueoxyglucose F 18
Study NCT04164342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surveys
Description: Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
Study NCT03363854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Study NCT00044291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatase inhibition
Study NCT03363854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study NCT03363854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study NCT01891942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: twitch by magstim
Study NCT03245853 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Riboflavin 5'-Phosphate
Description: Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
Study NCT02255253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: capsule,40mg per day,2 months
Study NCT02255253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: tablet, 25mg per day, 2 months
Study NCT01787149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Study NCT01787149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARDs
Study NCT05882409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education covers women's education on violence, conflict and awareness.
Study NCT02166996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture removal time 7 days
Description: To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
Study NCT02166996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal time14 days
Description: To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
Study NCT02081443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180mg
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
Study NCT02081443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
Study NCT00449267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular Lens
Description: Phacoemulsification with in the bag implantation of the IOL
Study NCT02683772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astral
Description: Astral ventilator
Study NCT02683772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astral
Description: Astral ventilator
Study NCT04601675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Ophthalmic and Intravitreal Dexamethasone
Description: Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
Study NCT04601675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Ophthalmic only
Description: Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.